Drug General Information (ID: DDI3I9EW42)
Drug Name			Inotuzumab ozogamicin		Drug Info		Deutetrabenazine		Drug Info
Drug Type		Monoclonal antibody				Small molecule
Therapeutic Class		Antineoplastics				Vmat2 Inhibitors

Mechanism of Inotuzumab ozogamicin-Deutetrabenazine Interaction (Severity Level: Moderate)
Additive CNS depression effects Click to Show/Hide Mechanism Graph
Drug Name		Inotuzumab ozogamicin				Deutetrabenazine
Mechanism 1		CNS depression effects				CNS depression effects
Key Mechanism Factor 1
		Factor Name		CNS depression effects
		Factor Description		CNS depressants are drugs that inhibit or suppress brain activity and can reduce mental and physical processes. Excessive CNS depression can lead to decreased heart rate, slow breathing (less than 10 breaths per minute), extreme confusion or loss of memory, nausea and vomiting, poor judgment, blue lips or fingertips, irritability and aggression, and clammy or cold skin.
Mechanism Description		Additive CNS depression effects by the combination of Inotuzumab ozogamicin and Deutetrabenazine
Increased risk of prolong QT interval Click to Show/Hide Mechanism Graph
Drug Name		Inotuzumab ozogamicin				Deutetrabenazine
Mechanism 2		Prolong QT interval				Prolong QT interval
Key Mechanism Factor 2
		Factor Name		QT interval
		Factor Description		Long QT syndrome is a heart signaling disorder that can cause a fast, chaotic heartbeat (arrhythmia). Many people may not exhibit symptoms, and usually the condition is detected during routine medical tests. In others, the most common symptoms include: sudden fainting, palpitations, dizziness, seizures, sudden death.
Mechanism Description		Increased risk of prolong QT interval by the combination of Inotuzumab ozogamicin and Deutetrabenazine

Recommended Action
Management		Coadministration of deutetrabenazine with other drugs that can prolong the QT interval should generally be avoided. Deutetrabenazine is not recommended for use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. If concomitant use is required, assessment of baseline QT interval and periodic monitoring during therapy may be considered. In addition, dosage reduction may be considered in patients on concurrent therapy with a strong CYP450 2D6 inhibitor, or in patients who are poor metabolizers of CYP450 2D6.

References
1	Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.